| Year |
Citation |
Score |
| 2020 |
Gerber NK, Yan SX, Levinson BA, Perez CA, Das IJ, Maisonet OG, Huppert N, No DK, Kelley J, Mistry N, Hitchen CJ, Goldberg JD. A prospective trial to compare deep inspiratory breath hold (DIBH) with prone breast irradiation. Practical Radiation Oncology. PMID 32014615 DOI: 10.1016/J.Ijrobp.2018.07.1613 |
0.338 |
|
| 2020 |
Marks DK, Axelrod D, Kwa M, Tray N, Hiotis K, Guth A, Novik Y, Speyer J, Ty V, Heguy A, Goldberg J, Darvishian F, Adams S. Abstract OT1-01-03: Impact of RANKL inhibition on tumor microenvironment of early-stage breast cancer, a pre-surgical trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot1-01-03 |
0.393 |
|
| 2020 |
Novik Y, Klar N, Zamora S, Kwa M, Speyer J, Oratz R, Muggia F, Meyers M, Hochman T, Goldberg J, Adams S. 129P Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort Annals of Oncology. 31: S59. DOI: 10.1016/J.Annonc.2020.03.232 |
0.323 |
|
| 2019 |
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, ... ... Goldberg JD, et al. . Blood. PMID 31515250 DOI: 10.1182/Blood.2019000428 |
0.313 |
|
| 2019 |
Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, ... ... Goldberg JD, et al. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. PMID 31363161 DOI: 10.1038/S41375-019-0524-7 |
0.328 |
|
| 2019 |
Formenti SC, Hawtin RE, Dixit N, Evensen E, Lee P, Goldberg JD, Li X, Vanpouille-Box C, Schaue D, McBride WH, Demaria S. Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. Journal For Immunotherapy of Cancer. 7: 177. PMID 31296256 DOI: 10.1186/S40425-019-0633-X |
0.376 |
|
| 2019 |
Kurz S, Silverman JS, Hochman T, Nayak L, Arrillaga-Romany I, Lee E, Patel A, Delara M, Hsu F, Imtiaz T, Magnelli L, Taylor J, Cloughesy T, Sulman E, Golfinos J, ... ... Goldberg JD, et al. ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM) Neuro-Oncology. 21: vi9-vi10. DOI: 10.1093/Neuonc/Noz175.036 |
0.304 |
|
| 2019 |
Zhovtis RL, Foley J, Chang I, Kister I, Cutter G, Metzger R, Goldberg JD, Li X, Riddle E, Smirnakis K, Yu B, Ren Z, Hotermans C, Ho P, Campbell N. Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program Revue Neurologique. 175: S102. DOI: 10.1016/J.Neurol.2019.01.272 |
0.315 |
|
| 2018 |
Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, ... ... Goldberg JD, et al. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Advances. 2: 3572-3580. PMID 30563881 DOI: 10.1182/Bloodadvances.2018019661 |
0.35 |
|
| 2018 |
Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, et al. Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis - Myeloproliferative Disorders Research Consortium 114 study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30205231 DOI: 10.1016/J.Bbmt.2018.09.001 |
0.309 |
|
| 2018 |
Shaikh F, Chew J, Hochman T, Purswani J, Maisonet O, Peat E, Huppert N, Cooper BT, Tam M, Goldberg JD, Perez CA, Formenti SC, Gerber NK. Hypofractionated Whole-Breast Irradiation in Women Less Than 50 Years Old Treated on 4 Prospective Protocols. International Journal of Radiation Oncology, Biology, Physics. PMID 29859789 DOI: 10.1016/J.Ijrobp.2018.04.034 |
0.346 |
|
| 2018 |
Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie M, Ratikan J, Felix C, Hwang L, Faull K, Sayre JW, Hurvitz S, Glaspy J, Comin-Anduix B, Demaria S, et al. Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29476019 DOI: 10.1158/1078-0432.Ccr-17-3322 |
0.344 |
|
| 2018 |
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger R, Goldberg JD, Li X, Riddle E, Smirnakis K, Yu B, Ren Z, Hotermans C, Ho P, Campbell N. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program Journal of Neurology, Neurosurgery & Psychiatry. 89: A29.2-A29. DOI: 10.1136/Jnnp-2018-Anzan.70 |
0.334 |
|
| 2017 |
Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, ... ... Goldberg JD, et al. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. PMID 29124456 DOI: 10.1007/S10549-017-4570-4 |
0.361 |
|
| 2017 |
Formenti SC, Golden EB, Goldberg JD, Li X, Taff J, Fenton-Kerimian MB, Chandrasekhar S, Demaria S, Novik Y. Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. Oncoimmunology. 6: e1274479. PMID 28405497 DOI: 10.1080/2162402X.2016.1274479 |
0.425 |
|
| 2017 |
Kwa MJ, Iwano A, Esteva FJ, Novik Y, Speyer JL, Oratz R, Meyers MI, Axelrod DM, Hogan R, Mendoza S, Goldberg JD, Muggia F, Adams S. Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer. Journal of Clinical Oncology. 35: TPS1124-TPS1124. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps1124 |
0.384 |
|
| 2017 |
Yacoub A, Mascarenhas J, Kosiorek HE, Prchal JT, Berenzon D, Baer MR, Ritchie EK, Silver RT, Kessler CM, Winton EF, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz DS, Rondelli D, ... ... Goldberg JD, et al. Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial Blood. 130: 321-321. DOI: 10.1182/Blood.V130.Suppl_1.321.321 |
0.323 |
|
| 2017 |
Schnabel F, Schwartz S, Hochman T, Chun J, Goldberg J. Abstract P5-16-26: National trends in neoadjuvant therapy for breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-16-26 |
0.356 |
|
| 2016 |
Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, Goldberg JD, Hoffman R. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leukemia Research. 53: 13-19. PMID 27930945 DOI: 10.1016/J.Leukres.2016.11.015 |
0.352 |
|
| 2016 |
Alexander M, Acosta Gonzalez G, Malerba S, Hochman T, Goldberg JD, Darvishian F. Multifocal Invasive Ductal Cancer: Distinguishing Independent Tumor Foci From Multiple Satellites. International Journal of Surgical Pathology. PMID 27831532 DOI: 10.1177/1066896916676586 |
0.333 |
|
| 2016 |
Cooper BT, Formenti-Ujlaki GF, Li X, Shin SM, Fenton-Kerimian M, Guth A, Roses DF, Hitchen CJ, Rosenstein BS, Dewyngaert JK, Goldberg JD, Formenti SC. Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. International Journal of Radiation Oncology, Biology, Physics. 95: 571-578. PMID 27131077 DOI: 10.1016/J.Ijrobp.2015.12.373 |
0.354 |
|
| 2016 |
Finkel MA, Cooper BT, Li X, Fenton-Kerimian M, Goldberg JD, Formenti SC. Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations. International Journal of Radiation Oncology, Biology, Physics. PMID 27045811 DOI: 10.1016/J.Ijrobp.2016.02.004 |
0.391 |
|
| 2016 |
Kwa M, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Bonakdar M, Abidoglu C, Kozhaya L, Li X, Joseph B, Iwano A, Friedman K, ... Goldberg J, et al. Abstract P2-11-11: Phase II trial of exemestane with immunomodulatory oral cyclophosphamide in metastatic hormone receptor (HR)-positive breast cancer: Prolonged progression-free survival (PFS) in patients with distinct T regulatory cell (Treg) profile Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-11-11 |
0.394 |
|
| 2015 |
Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, et al. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clinical Breast Cancer. PMID 26774497 DOI: 10.1016/J.Clbc.2015.11.006 |
0.301 |
|
| 2015 |
Hsu HC, Li X, Curtin JP, Goldberg JD, Schiff PB. Surveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapy. Frontiers in Oncology. 5: 81. PMID 25918687 DOI: 10.3389/Fonc.2015.00081 |
0.324 |
|
| 2015 |
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, ... ... Goldberg JD, et al. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunology Research. 3: 278-87. PMID 25633712 DOI: 10.1158/2326-6066.Cir-14-0202 |
0.314 |
|
| 2015 |
Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, ... ... Goldberg JD, et al. Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia & Lymphoma. 1-9. PMID 25563429 DOI: 10.3109/10428194.2014.1001986 |
0.316 |
|
| 2015 |
Cooper B, Di Brina L, Li X, Fenton-Kerimian M, Maisonet O, Guth A, Hitchen C, Jozsef G, DeWyngaert J, Goldberg J, Formenti S. Randomized Trial of Prone Accelerated Whole-Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed: Acute Toxicity and Associated Dosimetry International Journal of Radiation Oncology*Biology*Physics. 93: E38. DOI: 10.1016/J.Ijrobp.2015.07.639 |
0.404 |
|
| 2014 |
Adams S, Novik Y, Oratz R, Axelrod D, Speyer J, Tiersten A, Goldberg JD, Bhardwaj N, Unutmaz D, Demaria S, Formenti S. Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3204-5. PMID 25092780 DOI: 10.1200/Jco.2014.56.1282 |
0.381 |
|
| 2014 |
Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 124: 1183-91. PMID 24963042 DOI: 10.1182/Blood-2014-04-572545 |
0.304 |
|
| 2014 |
Saha A, Salley CG, Saigal P, Rolnitzky L, Goldberg J, Scott S, Olshefski R, Hukin J, Sands SA, Finlay J, Gardner SL. Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediatric Blood & Cancer. 61: 1644-52; quiz 1653-7. PMID 24789527 DOI: 10.1002/Pbc.25064 |
0.308 |
|
| 2014 |
Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Research : Bcr. 16: R32. PMID 24684785 DOI: 10.1186/Bcr3634 |
0.349 |
|
| 2014 |
Ashworth RE, Adams S, Fenton-Kerimian M, Sacris E, Speyer JL, Leichman CG, Janosky MD, Guo S, Goldberg JD, Novik Y, Formenti S. Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer: A feasibility trial. Journal of Clinical Oncology. 32: TPS1147-TPS1147. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1147 |
0.373 |
|
| 2014 |
Ling HT, Muggia F, Speyer JL, Curtin JP, Blank SV, Boyd LR, Pothuri B, Li X, Goldberg JD, Tiersten A. A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer. Journal of Clinical Oncology. 32: 5564-5564. DOI: 10.1200/Jco.2014.32.15_Suppl.5564 |
0.339 |
|
| 2013 |
Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). British Journal of Haematology. 161: 68-75. PMID 23330839 DOI: 10.1111/Bjh.12220 |
0.346 |
|
| 2013 |
Janosky MD, Demaria S, Novik Y, Oratz R, Tiersten A, Goldberg JD, Wang E, Marincola F, Formenti S, Adams S. Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3122 |
0.347 |
|
| 2013 |
Singh JC, Stein S, Volm M, Smith JA, Adams S, Meyers M, Speyer JL, Novik Y, Schneider R, Formenti S, Muggia F, Jhaveri KL, Goldberg JD, Heese S, Li X, et al. RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial. Journal of Clinical Oncology. 31: 1042-1042. DOI: 10.1200/Jco.2013.31.15_Suppl.1042 |
0.395 |
|
| 2013 |
Jhaveri K, Teplinsky E, Arzu R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine P, Hashmi S, Hoffman H, Paul L, Singh B, Goldberg J, Hochman T, et al. Abstract PD5-6: Sustained hyperactivated mTOR & JAK2/STAT3 pathways in inflammatory breast cancer (IBC): Evidence for mTOR plus JAK2 therapeutic targeting Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd5-6 |
0.34 |
|
| 2013 |
Fu, Axelrod D, Guth A, Goldberg J, Li X, Cartwright F, Haber J, Conley Y. Abstract P2-10-05: Lymphatic and pro-inflammatory candidate gene variations and breast-cancer related lymphedema Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-10-05 |
0.333 |
|
| 2013 |
Janosky M, Demaria S, Novik Y, Oratz R, Tiersten A, Goldberg J, Wang E, Marincola F, Fenton-Kerimian M, Maisonet O, Axelrod D, Sacris E, Levine P, Formenti S, Adams S. Abstract OT2-1-02: Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot2-1-02 |
0.377 |
|
| 2013 |
Vatner R, Demaria S, Fenton-Kerimian M, Novik Y, Oratz R, Tiersten A, Goldberg J, Adams S, Formenti S. Novel Combination of Toll-Like Receptor (TLR)-7 Agonist Imiquimod and Local Radiation Therapy in the Treatment of Metastatic Breast Cancer Involving the Skin or Chest Wall International Journal of Radiation Oncology*Biology*Physics. 87: S111. DOI: 10.1016/J.Ijrobp.2013.06.286 |
0.303 |
|
| 2012 |
Volm M, Novik Y, Speyer JL, Adams S, Omene CO, Meyers MI, Smith JA, Schneider R, Formenti S, Goldberg JD, Li X, Davis S, Beardslee B, Tiersten A. Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 108. PMID 28146722 DOI: 10.1200/Jco.2012.30.27_Suppl.108 |
0.332 |
|
| 2012 |
Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone vs supine positioning for breast cancer radiotherapy. Jama. 308: 861-3. PMID 22948692 DOI: 10.1001/2012.Jama.10759 |
0.331 |
|
| 2012 |
Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, Hochman T, Goldberg JD, Koch KM, Golfinos JG, Roland JT, Allen JC. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 14: 1163-70. PMID 22844108 DOI: 10.1093/Neuonc/Nos146 |
0.335 |
|
| 2012 |
Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6748-57. PMID 22767669 DOI: 10.1158/1078-0432.Ccr-12-1149 |
0.359 |
|
| 2012 |
Lymberis SC, deWyngaert JK, Parhar P, Chhabra AM, Fenton-Kerimian M, Chang J, Hochman T, Guth A, Roses D, Goldberg JD, Formenti SC. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. International Journal of Radiation Oncology, Biology, Physics. 84: 902-9. PMID 22494590 DOI: 10.1016/J.Ijrobp.2012.01.040 |
0.372 |
|
| 2012 |
Formenti SC, Hsu H, Fenton-Kerimian M, Roses D, Guth A, Jozsef G, Goldberg JD, Dewyngaert JK. Prone accelerated partial breast irradiation after breast-conserving surgery: five-year results of 100 patients. International Journal of Radiation Oncology, Biology, Physics. 84: 606-11. PMID 22494589 DOI: 10.1016/J.Ijrobp.2012.01.039 |
0.34 |
|
| 2012 |
Hardee ME, Raza S, Becker SJ, Jozsef G, Lymberis SC, Hochman T, Goldberg JD, DeWyngaert KJ, Formenti SC. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. International Journal of Radiation Oncology, Biology, Physics. 82: e415-23. PMID 22019349 DOI: 10.1016/J.Ijrobp.2011.06.1950 |
0.329 |
|
| 2012 |
Adams S, Hochman T, Huppert N, Dhage S, Checka C, Singh B, Speyer JL, Schneider R, Goldberg JD, Formenti S. Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy. Journal of Clinical Oncology. 30: e11064-e11064. DOI: 10.1200/Jco.2012.30.15_Suppl.E11064 |
0.394 |
|
| 2012 |
Ling HT, Smith JA, Kwa M, Dilawari AA, Cangiarella J, Goldberg JD, Hochman T, Andreopoulou E, Guth AA, Roses DF, Formenti S, Muggia F. Loss of nuclear p27KIP1 (p27) expression as a predictor of lymph node spread in T1 breast cancer. Journal of Clinical Oncology. 30: e11010-e11010. DOI: 10.1200/Jco.2012.30.15_Suppl.E11010 |
0.302 |
|
| 2012 |
Jain SS, Makeyev YG, Muggia F, Speyer JL, Curtin JP, Blank SV, Boyd LR, Pothuri B, Fishman D, Li X, Goldberg JD, Tiersten A. Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer. Journal of Clinical Oncology. 30: 5016-5016. DOI: 10.1200/Jco.2012.30.15_Suppl.5016 |
0.302 |
|
| 2012 |
Singh J, Volm M, Novik Y, Speyer J, Adams S, Omene C, Meyers M, Smith J, Schneider R, Formenti S, Goldberg J, Li X, Davis S, Beardslee B, Tiersten A. Abstract P5-20-05: A Phase 2 trial of RAD 001 and Carboplatin in patients with triple negative metastatic breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-20-05 |
0.368 |
|
| 2012 |
Osa E, Huppert N, Fenton-Kerimian M, Goldberg J, Jozsef G, DeWyngaert K, Formenti S. Prospective Randomized Trial of Prone Accelerated Whole Breast Radiation Therapy With a Concurrent Daily Versus Weekly Boost to the Tumor Bed: Acute Toxicity International Journal of Radiation Oncology*Biology*Physics. 84: S84-S85. DOI: 10.1016/J.Ijrobp.2012.07.223 |
0.332 |
|
| 2011 |
Wich LG, Ma MW, Price LS, Sidash S, Berman RS, Pavlick AC, Miller G, Sarpel U, Goldberg JD, Osman I. Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. Journal of Community Health. 36: 461-8. PMID 21080042 DOI: 10.1007/S10900-010-9328-4 |
0.309 |
|
| 2011 |
Mascarenhas J, Mercado A, Rodriguez A, Lu M, Kalvin C, Li X, Petersen B, Najfeld V, Goldberg JD, Hoffman R. Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis Blood. 118: 794-794. DOI: 10.1182/Blood.V118.21.794.794 |
0.353 |
|
| 2011 |
Singh J, Stein S, Volm M, Smith J, Novik Y, Speyer J, Adams S, Meyers M, Muggia F, Schneider R, Formenti S, Omene C, Choi H, Davis S, Goldberg J, et al. P1-17-07: Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-17-07 |
0.411 |
|
| 2010 |
Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Research and Treatment. 124: 723-32. PMID 20878462 DOI: 10.1007/S10549-010-1181-8 |
0.373 |
|
| 2010 |
Simpson NE, Lambert WM, Watkins R, Giashuddin S, Huang SJ, Oxelmark E, Arju R, Hochman T, Goldberg JD, Schneider RJ, Reiz LF, Soares FA, Logan SK, Garabedian MJ. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Research. 70: 8446-56. PMID 20847343 DOI: 10.1158/0008-5472.Can-10-1590 |
0.32 |
|
| 2010 |
Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, Goldberg J, Marchioli R, Hoffman R, Vannucchi AM. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology. 85: 616-9. PMID 20540156 DOI: 10.1002/Ajh.21754 |
0.362 |
|
| 2010 |
Rom WN, Goldberg JD, Addrizzo-Harris D, Watson HN, Khilkin M, Greenberg AK, Naidich DP, Crawford B, Eylers E, Liu D, Tan EM. Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. Bmc Cancer. 10: 234. PMID 20504322 DOI: 10.1186/1471-2407-10-234 |
0.621 |
|
| 2010 |
Adams S, Dewan Z, Meng T, Goldberg JD, Tiersten A, Bhardwaj N, Formenti S, Demaria S. Evaluation of toll-like receptor (TLR)-7 agonist imiquimod applied topically to breast cancer chest wall recurrences or skin metastases. Journal of Clinical Oncology. 28: TPS138-TPS138. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps138 |
0.346 |
|
| 2010 |
Wich LG, Ma MW, Berman RS, Pavlick AC, Shapiro RL, Miller G, Sarpel U, Price LS, Goldberg JD, Osman I. Impact of socioeconomic status on melanoma clinical presentation and prognosis in non-White melanoma patients. Journal of Clinical Oncology. 28: e16543-e16543. DOI: 10.1200/Jco.2010.28.15_Suppl.E16543 |
0.305 |
|
| 2010 |
Adams S, Lymberis SC, Chakravarthy AB, Spicer DV, Hochman T, Donach M, Goldberg JD, Schneider R, Pietenpol JA, Formenti S. Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC). Journal of Clinical Oncology. 28: 589-589. DOI: 10.1200/Jco.2010.28.15_Suppl.589 |
0.387 |
|
| 2010 |
Formenti S, Adams S, Chakravarthy AB, Lymberis SC, Spicer DV, Bauer JA, Volm M, Roses D, Goldberg JD, Pietenpol JA. Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC). Journal of Clinical Oncology. 28: 567-567. DOI: 10.1200/Jco.2010.28.15_Suppl.567 |
0.384 |
|
| 2010 |
Adams S, Chakravarthy AB, Donach M, Lymberis S, Singh B, Hochman T, Goldberg JD, Bauer JA, Spicer D, Pietenpol JA, Formenti SC. Abstract 5639: Preoperative concurrent paclitaxel and radiation in locally advanced breast cancer (LABC): Five-year outcomes on 105 patients Cancer Research. 70: 5639-5639. DOI: 10.1158/1538-7445.Am10-5639 |
0.396 |
|
| 2010 |
Schneider R, Formenti S, Chakravarthy A, Adams S, Spicer D, Lymberis S, Goldberg J, Pietenpol J. Five-year Results of Preoperative Paclitaxel with Concurrent Radiation Therapy in Locally Advanced Breast Cancer: Pathological Response Predicts for Survival International Journal of Radiation Oncology*Biology*Physics. 78: S219. DOI: 10.1016/J.Ijrobp.2010.07.525 |
0.363 |
|
| 2010 |
Lymberis S, Fenton-Kerimian M, Buck C, Rosenstein B, DeWyngaert K, Goldberg J, Formenti S. Phase III Study Comparing Prone Accelerated Whole Breast IMRT with a Daily vs. a Weekly Tumor Bed Boost: Interim Analysis Results International Journal of Radiation Oncology*Biology*Physics. 78: S215. DOI: 10.1016/J.Ijrobp.2010.07.517 |
0.336 |
|
| 2010 |
Chakravarthy A, Adams S, Spicer D, Lymberis S, Goldberg J, Schneider R, Pietenpol J, Formenti S. Five-year Local Control Results of Preoperative Paclitaxel with Concurrent Radiation Therapy in Locally Advanced Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 78: S209-S210. DOI: 10.1016/J.Ijrobp.2010.07.505 |
0.313 |
|
| 2009 |
Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nature Cell Biology. 11: 903-8. PMID 19525934 DOI: 10.1038/Ncb1900 |
0.315 |
|
| 2009 |
Hexner E, Goldberg JD, Prchal JT, Demakos EP, Swierczek S, Weinberg RS, Tripodi J, Najfeld V, Carroll M, Marchioli R, Silverman LR, Hoffman R. A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Blood. 114: 754-754. DOI: 10.1182/Blood.V114.22.754.754 |
0.324 |
|
| 2009 |
Kaufmann K, Swierczek S, Shang S, Gruender A, Weinberg RS, Rambaldi A, Marchioli R, Hickmann K, Goldberg JD, Prchal JT, Pahl HL. Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms. Blood. 114: 4968-4968. DOI: 10.1182/Blood.V114.22.4968.4968 |
0.302 |
|
| 2009 |
Mascarenhas J, Wang X, Rodriguez A, Xu M, Gorman E, Zhang W, Goldberg JD, Najfeld V, Hoffman R. A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF). Blood. 114: 308-308. DOI: 10.1182/Blood.V114.22.308.308 |
0.329 |
|
| 2009 |
Adams S, Donach M, Singh B, Goldberg J, Formenti S. Lack of Hormone Receptor Expression is Associated with Pathological Response in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Concurrent Chemoradiation International Journal of Radiation Oncology*Biology*Physics. 75: S220-S221. DOI: 10.1016/J.Ijrobp.2009.07.510 |
0.341 |
|
| 2008 |
Shao Y, Mukhi V, Goldberg JD. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority. Statistics in Medicine. 27: 504-19. PMID 17854052 DOI: 10.1002/Sim.3028 |
0.738 |
|
| 2007 |
Formenti SC, Gidea-Addeo D, Goldberg JD, Roses DF, Guth A, Rosenstein BS, DeWyngaert KJ. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2236-42. PMID 17470849 DOI: 10.1200/Jco.2006.09.1041 |
0.343 |
|
| 2007 |
Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 20: 233-41. PMID 17192789 DOI: 10.1038/Modpathol.3800734 |
0.625 |
|
| 2007 |
Barosi G, Gattoni E, Barbui T, Vannucchi AM, Rambaldi A, Silverman L, Goldberg J, Marchioli R, Hoffman R. A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis. Blood. 110: 3540-3540. DOI: 10.1182/Blood.V110.11.3540.3540 |
0.328 |
|
| 2007 |
Formenti S, Parhar P, Goldberg J, DeWyngaert J. Prospective Trial of Individual Optimal Positioning (Prone Versus Supine) for Whole Breast Radiotherapy: Results of the First 168 Patients International Journal of Radiation Oncology*Biology*Physics. 69: S74. DOI: 10.1016/J.Ijrobp.2007.07.133 |
0.349 |
|
| 2005 |
Sands SA, Milner JS, Goldberg J, Mukhi V, Moliterno JA, Maxfield C, Wisoff JH. Quality of life and behavioral follow-up study of pediatric survivors of craniopharyngioma. Journal of Neurosurgery. 103: 302-11. PMID 16270681 DOI: 10.3171/Ped.2005.103.4.0302 |
0.721 |
|
| 2005 |
Axelrod FB, Goldberg JD, Rolnitzky L, Mull J, Mann SP, Gold von Simson G, Berlin D, Slaugenhaupt SA. Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society. 15: 284-91. PMID 16032383 DOI: 10.1007/S10286-005-0288-1 |
0.318 |
|
| 2005 |
Hiotis K, Ye W, Sposto R, Goldberg J, Mukhi V, Skinner K. The importance of location in determining breast conservation rates. American Journal of Surgery. 190: 18-22. PMID 15972165 DOI: 10.1016/J.Amjsurg.2004.12.002 |
0.746 |
|
| 2005 |
Formenti S, Mitchell J, Goldberg J, Magnolfi C, Rosenstein B, Remon S, DeWyngaert K. NYU 03-30: Accelerated IMRT with Concomitant Boost after Breast Conservation Surgery. Preliminary Clinical Results in 70 Patients International Journal of Radiation Oncology*Biology*Physics. 63: S181-S182. DOI: 10.1016/J.Ijrobp.2005.07.316 |
0.344 |
|
| 2004 |
Formenti SC, Truong MT, Goldberg JD, Mukhi V, Rosenstein B, Roses D, Shapiro R, Guth A, Dewyngaert JK. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. International Journal of Radiation Oncology, Biology, Physics. 60: 493-504. PMID 15380584 DOI: 10.1016/J.Ijrobp.2004.04.036 |
0.769 |
|
| 2004 |
Bekker AY, Basile J, Gold M, Riles T, Adelman M, Cuff G, Mathew JP, Goldberg JD. Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects. Journal of Neurosurgical Anesthesiology. 16: 126-35. PMID 15021281 DOI: 10.1097/00008506-200404000-00004 |
0.319 |
|
| 2004 |
Formenti SC, Goldberg J, Rosenstein B, Dewyngaert K. Prone accelerated partial breast irradiation (five fractions) after breast conservation therapy with heart and lung sparing Journal of Clinical Oncology. 22: 870-870. DOI: 10.1200/Jco.2004.22.90140.870 |
0.319 |
|
| 2004 |
Formenti S, Truong M, Goldberg J, Rosenstein B, DeWeyngaert K. Phase I-II study of prone accelerated partial breast irradiation International Journal of Radiation Oncology*Biology*Physics. 60: S397. DOI: 10.1016/J.Ijrobp.2004.07.269 |
0.307 |
|
| 2003 |
Donahue BR, Goldberg JD, Golfinos JG, Knopp EA, Comiskey J, Rush SC, Han K, Mukhi V, Cooper JS. Importance of MR technique for stereotactic radiosurgery. Neuro-Oncology. 5: 268-74. PMID 14565164 DOI: 10.1215/S1152851703000048 |
0.748 |
|
| 2003 |
Truong M, Rosenstein B, Goldberg J, Cho C, DeWyngaert K, Formenti S. Hypo-fractionated partial breast radiation after breast-conserving surgery: preliminary clinical results and dose volume histogram (DVH) analysis International Journal of Radiation Oncology*Biology*Physics. 57: S367-S368. DOI: 10.1016/S0360-3016(03)01276-8 |
0.33 |
|
| 1985 |
Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Investigational New Drugs. 3: 123-132. PMID 3894276 DOI: 10.1007/Bf00174159 |
0.346 |
|
| 1984 |
Donovan PB, Kaplan ME, Goldberg JD, Tatarsky I, Najean Y, Silberstein EB, Knospe WH, Laszlo J, Mack K, Berk PD. Treatment of polycythemia vera with hydroxyurea American Journal of Hematology. 17: 329-334. PMID 6496458 DOI: 10.1002/Ajh.2830170402 |
0.326 |
|
| 1983 |
Chabon AB, Goldberg JD, Venet L. Carcinoma of the breast. Interrelationships among histopathologic features, estrogen receptor activity, and age of the patient Human Pathology. 14: 368-372. PMID 6832775 DOI: 10.1016/S0046-8177(83)80124-5 |
0.335 |
|
| 1983 |
Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, Wallach RC, Kabakow B, Rodin J. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). American Journal of Obstetrics and Gynecology. 145: 955-67. PMID 6404174 DOI: 10.1016/0002-9378(83)90849-9 |
0.354 |
|
| 1983 |
Bruckner HW, Cohen CJ, Goldberg JD, Kabakow B, Wallach RC, Deppe G, Reisman AZ, Gusberg SB, Holland JF. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer American Journal of Obstetrics and Gynecology. 145: 653-658. PMID 6402934 DOI: 10.1016/0002-9378(83)90569-0 |
0.35 |
|
| 1983 |
Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial Gastroenterology. 85: 351-357. PMID 6305758 DOI: 10.1016/0016-5085(83)90323-2 |
0.339 |
|
| 1983 |
Sachar DB, Wolfson DM, Greenstein AJ, Goldberg J, Styczynski R, Janowitz HD. Risk factors for postoperative recurrence of Crohn's disease Gastroenterology. 85: 917-921. DOI: 10.1016/0016-5085(83)90444-4 |
0.302 |
|
| 1982 |
Weick JK, Donovan PB, Najean Y, Dresch C, Pisciotta AV, Cooperberg AA, Goldberg JD. The use of cimetidine for the treatment of pruritus in polycythemia vera. Archives of Internal Medicine. 142: 241-2. PMID 7059251 DOI: 10.1001/Archinte.1982.003401500410010 |
0.31 |
|
| 1982 |
Keusch GT, Ambinder EP, Kovacs I, Goldberg JD, Phillips DM, Holland JF. Role of opsonins in clinical response to granulocyte transfusion in granulocytopenic patients The American Journal of Medicine. 73: 552-563. PMID 6751084 DOI: 10.1016/0002-9343(82)90336-9 |
0.303 |
|
| 1982 |
Brubaker LH, Briére J, Laszlo J, Kraut E, Landaw SA, Peterson P, Goldberg J, Donovan P. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Jama Internal Medicine. 142: 1533-1537. DOI: 10.1001/Archinte.1982.00340210131023 |
0.304 |
|
| 1981 |
Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N. A Comparison of Androgens for Anemia in Patients on Hemodialysis The New England Journal of Medicine. 304: 871-875. PMID 7010161 DOI: 10.1056/Nejm198104093041504 |
0.307 |
|
| 1981 |
Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. The New England Journal of Medicine. 304: 441-7. PMID 7005681 DOI: 10.1056/Nejm198102193040801 |
0.328 |
|
| 1981 |
Ambinder EP, Button GR, Cheung T, Goldberg JD, Holland JF. Filtration versus gravity leukapheresis in febrile granulocytopenic patients: a randomized prospective trial. Blood. 57: 836-41. PMID 6938259 DOI: 10.1182/Blood.V57.5.836.836 |
0.303 |
|
| 1981 |
Bruckner HW, Cohen CJ, Goldberg JD, Kabakow B, Wallach RC, Deppe G, Greenspan EM, Gusberg SB, Holland JF. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin Cancer. 47: 2288-2294. PMID 6784917 DOI: 10.1002/1097-0142(19810501)47:9<2288::Aid-Cncr2820470931>3.0.Co;2-3 |
0.355 |
|
| 1974 |
Shapiro S, Goldberg JD, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening American Journal of Epidemiology. 100: 357-366. PMID 4417355 DOI: 10.1093/Oxfordjournals.Aje.A112046 |
0.314 |
|
| Show low-probability matches. |